Fig. 2From: Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME studyKaplan–Meier curves and Cox proportional hazard-model for time-to CID during 52 weeks of treatment. b.i.d., twice daily; CID, clinically important deterioration; IND/GLY, indacaterol/glycopyrronium; o.d., once daily; SFC, salmeterol/fluticasoneBack to article page